You just read:

FDA Advisory Committee Votes in Favor of Lilly's CYRAMZA® (ramucirumab) as First-Line Treatment for Metastatic EGFR-Mutated Non-Small Cell Lung Cancer

News provided by

Eli Lilly and Company

Feb 26, 2020, 19:27 ET